- Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow upSong, Yuqin; Zhou, Keshu; Li, Dengju; Hu, Jianda; Zou, Dehui; Gao, Sujun; Yang, Haiyan; Zhang, Huilai; Ji, Jie; Xu, Wei; Feng, Ru; Jin, Jie; Lyu, Fangfang; Fang, Cheng; Xu, Sheng; Zhu, Jun65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
- Phase 1 dose escalation study of MH048, a novel and non-covalent BTK inhibitor in patients with relapsed or refractory B-cell malignancies.Cao, Guoqing; Jin, Zhengming; Li, Yuhua; Zhang, Liling; Shi, Junwei; Jin, JieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
- Frontline Treatment with Zanubrutinib Plus Rituximab (ZR) Followed By Short Course R-Dhaox Shows Potent Efficacy in Patients with Mantle Cell Lymphoma (MCL) - Preliminary Results of Phase II CHESS Clinical TrialCai, Qingqing; Xia, Yi; Liu, Panpan; Zhang, Yuchen; Huang, Huiqiang; Gao, Yan; Li, Guowei; Sun, Xiuhua; Pan, Xueyi64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), New Orleans, LA, 2022-12-10 To 2022-12-13.被引 2
会议论文
Pirtobrutinib, a Non-Covalent (reversible) BTK Inhibitor, in Mantle Cell Lymphoma Patients Previously Treated with a Covalent BTK Inhibitor: Results from a China Phase 2 Study
15阅读
